Refine
Year of publication
Document Type
- Journal article (7411)
- Doctoral Thesis (2756)
- Book article / Book chapter (133)
- Conference Proceeding (108)
- Preprint (106)
- Working Paper (66)
- Review (43)
- Report (27)
- Master Thesis (26)
- Book (20)
- Other (13)
- Bachelor Thesis (5)
- Jahresbericht (1)
- Habilitation (1)
- Study Thesis (term paper) (1)
Language
- English (10717) (remove)
Keywords
- Toxikologie (119)
- Medizin (99)
- inflammation (89)
- Biochemie (85)
- Psychologie (85)
- cancer (74)
- Organische Chemie (68)
- gene expression (68)
- Anorganische Chemie (66)
- Maus (64)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (1866)
- Graduate School of Life Sciences (773)
- Physikalisches Institut (577)
- Institut für Psychologie (478)
- Neurologische Klinik und Poliklinik (372)
- Institut für Anorganische Chemie (353)
- Institut für Organische Chemie (353)
- Medizinische Klinik und Poliklinik II (348)
- Institut für Molekulare Infektionsbiologie (345)
- Medizinische Klinik und Poliklinik I (344)
- Institut für Informatik (340)
- Institut für Pharmakologie und Toxikologie (291)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (269)
- Institut für Virologie und Immunbiologie (266)
- Rudolf-Virchow-Zentrum (263)
- Institut für Geographie und Geologie (259)
- Julius-von-Sachs-Institut für Biowissenschaften (245)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (229)
- Institut für Theoretische Physik und Astrophysik (226)
- Pathologisches Institut (211)
- Institut für Pharmazie und Lebensmittelchemie (208)
- Institut für Mathematik (197)
- Klinik und Poliklinik für Nuklearmedizin (196)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (195)
- Lehrstuhl für Orthopädie (162)
- Institut für Physikalische und Theoretische Chemie (160)
- Institut für Anatomie und Zellbiologie (157)
- Kinderklinik und Poliklinik (153)
- Institut für Klinische Epidemiologie und Biometrie (152)
- Neurochirurgische Klinik und Poliklinik (148)
- Institut für Hygiene und Mikrobiologie (140)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (137)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (134)
- Institut für Humangenetik (131)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (130)
- Institut für Klinische Neurobiologie (128)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (127)
- Abteilung für Funktionswerkstoffe der Medizin und der Zahnheilkunde (121)
- Klinik und Poliklinik für Strahlentherapie (88)
- Comprehensive Cancer Center Mainfranken (84)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (84)
- Institut für Psychologie (bis Sept. 2007) (80)
- Lehrstuhl für Biochemie (79)
- Neuphilologisches Institut - Moderne Fremdsprachen (78)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (77)
- Medizinische Fakultät (76)
- Fakultät für Physik und Astronomie (74)
- Frauenklinik und Poliklinik (74)
- Institut für Experimentelle Biomedizin (74)
- Institut Mensch - Computer - Medien (72)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (68)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (63)
- Physiologisches Institut (61)
- Institut für Sportwissenschaft (56)
- Institut für Funktionsmaterialien und Biofabrikation (54)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (50)
- Betriebswirtschaftliches Institut (48)
- Institut für deutsche Philologie (48)
- Volkswirtschaftliches Institut (48)
- Institut für Medizinische Strahlenkunde und Zellforschung (47)
- Urologische Klinik und Poliklinik (47)
- Center for Computational and Theoretical Biology (44)
- Augenklinik und Poliklinik (43)
- Institut für Klinische Biochemie und Pathobiochemie (40)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (38)
- Graduate School of Science and Technology (36)
- Fakultät für Biologie (35)
- Lehrstuhl für Molekulare Psychiatrie (34)
- Fakultät für Chemie und Pharmazie (29)
- Institut für Kulturwissenschaften Ost- und Südasiens (27)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (27)
- Institut für Politikwissenschaft und Soziologie (25)
- Institut für Allgemeinmedizin (19)
- Institut für Mineralogie und Kristallstrukturlehre (18)
- Poliklinik für Zahnärztliche Prothetik (18)
- Institut für Geologie (17)
- Institut für Altertumswissenschaften (15)
- Institut für Geographie (15)
- Institut für Psychotherapie und Medizinische Psychologie (15)
- Institut für Rechtsmedizin (13)
- Abteilung für Parodontologie (in der Poliklinik für Zahnerhaltung und Parodontologie) (12)
- Graduate School of the Humanities (12)
- Missionsärztliche Klinik (12)
- Institut für Biblische Theologie (11)
- Institut für Klinische Transfusionsmedizin und Hämotherapie (11)
- Poliklinik für Zahnerhaltung und Parodontologie (11)
- Universität Würzburg (11)
- Institut für Pädagogik (10)
- Institut für Systemimmunologie (10)
- Institut für Medizinische Lehre und Ausbildungsforschung (9)
- Institut für Philosophie (9)
- Philosophische Fakultät (Histor., philolog., Kultur- und geograph. Wissensch.) (9)
- Medizinische Klinik (bis 2004) (8)
- Poliklinik für Kieferorthopädie (8)
- Wirtschaftswissenschaftliche Fakultät (8)
- Graduate School of Law, Economics, and Society (6)
- Institut für Sonderpädagogik (6)
- Katholisch-Theologische Fakultät (6)
- Fakultät für Humanwissenschaften (Philos., Psycho., Erziehungs- u. Gesell.-Wissensch.) (5)
- Fakultät für Mathematik und Informatik (5)
- Institut für Altertumswissenschaften (bis Sept. 2007) (5)
- Institut für Evangelische Theologie und Religionspädagogik (5)
- Institut für Paläontologie (5)
- Institut für Praktische Theologie (5)
- Klinik für Anaesthesiologie (bis 2003) (5)
- Lehrstuhl für Silicatchemie (5)
- Neuphilologisches Institut - Moderne Fremdsprachen (bis 2007) (5)
- Sportzentrum (5)
- Institut für Internationales Recht, Europarecht und Europäisches Privatrecht (4)
- Klinik und Polikliniken für Zahn-, Mund- und Kieferkrankheiten (4)
- Abteilung für Forensische Psychiatrie (3)
- Institut für Anglistik und Amerikanistik (3)
- Institut für Geschichte der Medizin (3)
- Juristische Fakultät (3)
- Fachgruppe Didaktik der Biologie (2)
- Institut für Geschichte (2)
- Institut für Gesellschafts-, Steuer- und Arbeitsrecht (2)
- Institut für Musikforschung (2)
- Institut für Orientalische Philologie (2)
- Institut für Systematische Theologie (2)
- Institut für medizinische Datenwissenschaften (2)
- Medizinische Poliklinik (bis 2004) (2)
- Botanischer Garten (1)
- Graduate Schools (1)
- Institut für Bürgerliches Recht und Zivilprozessrecht (1)
- Institut für Historische Theologie (1)
- Institut für Kulturwissenschaften Ost- und Südasiens (bis Sept. 2007) (1)
- Institut für Politische Wissenschaft (1)
- Klinik und Poliklinik für Haut- und Geschlechtskrankheiten (bis 2003) (1)
- Krankenhaus für Psychiatrie, Psychotherapie und Neurologie des Bezirks Unterfranken (1)
- Rechenzentrum (1)
- Zentrum für Sprachen (1)
Schriftenreihe
- Cultural Animal Studies, Band 3 (24)
- Berichte aus der Informatik (1)
- Deuterocanonical and Cognate Literature Studies (1)
- Deuterocanonical and Cognate Literature Yearbook (1)
- International Archives of the History of Ideas / Archives internationales d’histoire des idées 242 (1)
- Methods in Molecular Biology 2533 (1)
- Methods in Molecular Biology; 2643 (1)
Sonstige beteiligte Institutionen
- VolkswagenStiftung (24)
- Johns Hopkins School of Medicine (17)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (7)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (5)
- Fraunhofer-Institut für Silicatforschung ISC (5)
- Helmholtz Institute for RNA-based Infection Research (HIRI) (5)
- Johns Hopkins University School of Medicine (5)
- Wilhelm-Conrad-Röntgen-Forschungszentrum für komplexe Materialsysteme (5)
- Bernhard-Heine-Centrum für Bewegungsforschung (4)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (4)
ResearcherID
- B-1911-2015 (1)
- B-4606-2017 (1)
- C-2593-2016 (1)
- D-1221-2009 (1)
- D-1250-2010 (1)
- I-5818-2014 (1)
- J-8841-2015 (1)
- M-1240-2017 (1)
- N-2030-2015 (1)
- N-3741-2015 (1)
Introduction
We investigated a slow-cortical potential (SCP) neurofeedback therapy approach for rehabilitating chronic attention deficits after stroke. This study is the first attempt to train patients who survived stroke with SCP neurofeedback therapy.
Methods
We included N = 5 participants in a within-subjects follow-up design. We assessed neuropsychological and psychological performance at baseline (4 weeks before study onset), before study onset, after neurofeedback training, and at 3 months follow-up. Participants underwent 20 sessions of SCP neurofeedback training.
Results
Participants learned to regulate SCPs toward negativity, and we found indications for improved attention after the SCP neurofeedback therapy in some participants. Quality of life improved throughout the study according to engagement in activities of daily living. The self-reported motivation was related to mean SCP activation in two participants.
Discussion
We would like to bring attention to the potential of SCP neurofeedback therapy as a new rehabilitation method for treating post-stroke cognitive deficits. Studies with larger samples are warranted to corroborate the results.
Background
Cognitive impairment is a major comorbidity in patients with chronic heart failure (HF) with a wide range of phenotypes. In this study, we aimed to identify and compare different clusters of cognitive deficits.
Methods
The prospective cohort study “Cognition.Matters-HF” recruited 147 chronic HF patients (aged 64.5 ± 10.8 years; 16.2% female) of any etiology. All patients underwent extensive neuropsychological testing. We performed a hierarchical cluster analysis of the cognitive domains, such as intensity of attention, visual/verbal memory, and executive function. Generated clusters were compared exploratively with respect to the results of cardiological, neurological, and neuroradiological examinations without correction for multiple testing.
Results
Dendrogram and the scree plot suggested three distinct cognitive profiles: In the first cluster, 42 patients (28.6%) performed without any deficits in all domains. Exclusively, the intensity of attention deficits was seen in the second cluster, including 55 patients (37.4%). A third cluster with 50 patients (34.0%) was characterized by deficits in all cognitive domains. Age (p = 0.163) and typical clinical markers of chronic HF, such as ejection fraction (p = 0.222), 6-min walking test distance (p = 0.138), NT-proBNP (p = 0.364), and New York Heart Association class (p = 0.868) did not differ between clusters. However, we observed that women (p = 0.012) and patients with previous cardiac valve surgery (p = 0.005) prevailed in the “global deficits” cluster and the “no deficits” group had a lower prevalence of underlying arterial hypertension (p = 0.029). Total brain volume (p = 0.017) was smaller in the global deficit cluster, and serum levels of glial fibrillary acidic protein were increased (p = 0.048).
Conclusion
Apart from cognitively healthy and globally impaired HF patients, we identified a group with deficits only in the intensity of attention. Women and patients with previous cardiac valve surgery are at risk for global cognitive impairment when suffering HF and could benefit from special multimodal treatment addressing the psychosocial condition.
Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
(2023)
Background
Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.
Case presentation
We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.
Conclusion
Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.
Mutations in the mitochondrial-DNA or mitochondria related nuclear-encoded-DNA lead to various multisystemic disorders collectively termed mitochondrial diseases. One in three cases of mitochondrial disease affects the heart muscle, which is called mitochondrial cardiomyopathy (MCM) and is associated with hypertrophic, dilated, and noncompact cardiomyopathy. The heart is an organ with high energy demand, and mitochondria occupy 30%–40% of its cardiomyocyte-cell volume. Mitochondrial dysfunction leads to energy depletion and has detrimental effects on cardiac performance. However, disease development and progression in the context of mitochondrial and nuclear DNA mutations, remains incompletely understood. The system of induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) is an excellent platform to study MCM since the unique genetic identity to their donors enables a robust recapitulation of the predicted phenotypes in a dish on a patient-specific level. Here, we focus on recent insights into MCM studied by patient-specific iPSC-CM and further discuss research gaps and advances in metabolic maturation of iPSC-CM, which is crucial for the study of mitochondrial dysfunction and to develop novel therapeutic strategies.
Objectives
The spectrum of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) represents highly inflammatory rheumatic diseases. Patients mostly report severe physical impairment. Possible consequences for mental health have been scarcely studied. The aim of this study was to investigate psychological well-being in the context of GCA and PMR.
Methods
Cross-sectional study with N = 100 patients with GCA and/or PMR (GCA-PMR). Patient-reported outcomes (PROs) were measured using the Short Form 36 Version 2 (SF-36v2) and visual analog scale (VAS) assessment. Moreover, the Patient Health Questionnaire 9 (PHQ-9) was used in 35 of 100 patients to detect depression. To compare PROs with physician assessment, VAS was also rated from physician perspective. To assess a possible association with inflammation itself, serological parameters of inflammation (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]) were included.
Results
In all scales of the SF-36v2 except General Health (GH) and in the physical and mental sum score (PCS, MCS), a significant impairment compared to the German reference collective was evident (MCS: d = 0.533, p < 0.001). In the PHQ-9 categorization, 14 of the 35 (40%) showed evidence of major depression disorder. VAS Patient correlated significantly with PHQ-9 and SF-36 in all categories, while VAS Physician showed only correlations to physical categories and not in the mental dimensions. Regarding inflammatory parameters, linear regression showed CRP to be a complementary significant positive predictor of mental health subscale score, independent of pain.
Conclusion
PRO show a relevant impairment of mental health up to symptoms of major depression disorder. The degree of depressive symptoms is also distinctly associated with the serological inflammatory marker CRP.
Introduction
Pro-thrombotic events are one of the prevalent causes of intensive care unit (ICU) admissions among COVID-19 patients, although the signaling events in the stimulated platelets are still unclear.
Methods
We conducted a comparative analysis of platelet transcriptome data from healthy donors, ICU, and non-ICU COVID-19 patients to elucidate these mechanisms. To surpass previous analyses, we constructed models of involved networks and control cascades by integrating a global human signaling network with transcriptome data. We investigated the control of platelet hyperactivation and the specific proteins involved.
Results
Our study revealed that control of the platelet network in ICU patients is significantly higher than in non-ICU patients. Non-ICU patients require control over fewer proteins for managing platelet hyperactivity compared to ICU patients. Identification of indispensable proteins highlighted key subnetworks, that are targetable for system control in COVID-19-related platelet hyperactivity. We scrutinized FDA-approved drugs targeting indispensable proteins and identified fostamatinib as a potent candidate for preventing thrombosis in COVID-19 patients.
Discussion
Our findings shed light on how SARS-CoV-2 efficiently affects host platelets by targeting indispensable and critical proteins involved in the control of platelet activity. We evaluated several drugs for specific control of platelet hyperactivity in ICU patients suffering from platelet hyperactivation. The focus of our approach is repurposing existing drugs for optimal control over the signaling network responsible for platelet hyperactivity in COVID-19 patients. Our study offers specific pharmacological recommendations, with drug prioritization tailored to the distinct network states observed in each patient condition. Interactive networks and detailed results can be accessed at https://fostamatinib.bioinfo-wuerz.eu/.
Zinc (Zn2+) is considered as important mediator of immune cell function, thrombosis and haemostasis. However, our understanding of the transport mechanisms that regulate Zn2+ homeostasis in platelets is limited. Zn2+ transporters, ZIPs and ZnTs, are widely expressed in eukaryotic cells. Using mice globally lacking ZIP1 and ZIP3 (ZIP1/3 DKO), our aim was to explore the potential role of these Zn2+ transporters in maintaining platelet Zn2+ homeostasis and in the regulation of platelet function. While ICP-MS measurements indicated unaltered overall Zn2+ concentrations in platelets of ZIP1/3 DKO mice, we observed a significantly increased content of FluoZin3-stainable free Zn2+, which, however, appears to be released less efficiently upon thrombin-stimulated platelet activation. On the functional level, ZIP1/3 DKO platelets exhibited a hyperactive response towards threshold concentrations of G protein-coupled receptor (GPCR) agonists, while immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptor agonist signalling was unaffected. This resulted in enhanced platelet aggregation towards thrombin, bigger thrombus volume under flow ex vivo and faster in vivo thrombus formation in ZIP1/3 DKO mice. Molecularly, augmented GPCR responses were accompanied by enhanced Ca2+ and PKC, CamKII and ERK1/2 signalling. The current study thereby identifies ZIP1 and ZIP3 as important regulators for the maintenance of platelet Zn2+ homeostasis and function.
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
(2023)
Fibroblast growth factor (FGF)-inducible 14 (Fn14) activates the classical and alternative NFκB (nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells) signaling pathway but also enhances tumor necrosis factor (TNF)-induced cell death. Fn14 expression is upregulated in non-hematopoietic cells during tissue injury and is also often highly expressed in solid cancers. In view of the latter, there were and are considerable preclinical efforts to target Fn14 for tumor therapy, either by exploiting Fn14 as a target for antibodies with cytotoxic activity (e.g. antibody-dependent cellular cytotoxicity (ADCC)-inducing IgG variants, antibody drug conjugates) or by blocking antibodies with the aim to interfere with protumoral Fn14 activities. Noteworthy, there are yet no attempts to target Fn14 with agonistic Fc effector function silenced antibodies to unleash the proinflammatory and cell death-enhancing activities of this receptor for tumor therapy. This is certainly not at least due to the fact that anti-Fn14 antibodies only act as effective agonists when they are presented bound to Fcγ receptors (FcγR). Thus, there are so far no antibodies that robustly and selectively engage Fn14 signaling without triggering unwanted FcγR-mediated activities. In this study, we investigated a panel of variants of the anti-Fn14 antibody 18D1 of different valencies and domain architectures with respect to their inherent FcγR-independent ability to trigger Fn14-associated signaling pathways. In contrast to conventional 18D1, the majority of 18D1 antibody variants with four or more Fn14 binding sites displayed a strong ability to trigger the alternative NFκB pathway and to enhance TNF-induced cell death and therefore resemble in their activity soluble (TNF)-like weak inducer of apoptosis (TWEAK), one form of the natural occurring ligand of Fn14. Noteworthy, activation of the classical NFκB pathway, which naturally is predominately triggered by membrane-bound TWEAK but not soluble TWEAK, was preferentially observed with a subset of constructs containing Fn14 binding sites at opposing sites of the IgG scaffold, e.g. IgG1-scFv fusion proteins. A superior ability of IgG1-scFv fusion proteins to trigger classical NFκB signaling was also observed with the anti-Fn14 antibody PDL192 suggesting that we identified generic structures for Fn14 antibody variants mimicking soluble and membrane-bound TWEAK.
Introduction
IgG4 autoantibodies against paranodal proteins are known to induce acute-onset and often severe sensorimotor autoimmune neuropathies. How autoantibodies reach their antigens at the paranode in spite of the myelin barrier is still unclear.
Methods
We performed in vitro incubation experiments with patient sera on unfixed and unpermeabilized nerve fibers and in vivo intraneural and intrathecal passive transfer of patient IgG to rats, to explore the access of IgG autoantibodies directed against neurofascin-155 and contactin-1 to the paranodes and their pathogenic effect.
Results
We found that in vitro incubation resulted in weak paranodal binding of anti-contactin-1 autoantibodies whereas anti-neurofascin-155 autoantibodies bound to the nodes more than to the paranodes. After short-term intraneural injection, no nodal or paranodal binding was detectable when using anti-neurofascin-155 antibodies. After repeated intrathecal injections, nodal more than paranodal binding could be detected in animals treated with anti-neurofascin-155, accompanied by sensorimotor neuropathy. In contrast, no paranodal binding was visible in rats intrathecally injected with anti-contactin-1 antibodies, and animals remained unaffected.
Conclusion
These data support the notion of different pathogenic mechanisms of anti-neurofascin-155 and anti-contactin-1 autoantibodies and different accessibility of paranodal and nodal structures.
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
(2023)
In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.